In this episode of Biotech Banter, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso highlight Chelsea Therapeutics (NASDAQ:CHTP) as the biotech of the week.
Chelsea already has a drug called Northera approved for low blood pressure caused by neurological disorders such as Parkinson's Disease. The biotech is also testing Northera for other indications, including intradialytic hypotension and fibromyalgia, and has a rheumatoid arthritis drug, CH-4051, that's further back in the clinic.
While Northera isn't going to be a blockbuster anytime soon, it doesn't really have to be considering Chelsea Therapuetics has a market cap under $400 million. There are plenty of drug companies with no drugs on the market that are valued higher than that.
Watch the video below for the rest of Brian's and Max's take on Chelsea Therapeutics.
Brian Orelli, Max Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.